AGP Picks
View all

French STEM Today
Provided by AGP

French STEM Today: Press Releases

Browse our comprehensive archive of press releases by date.
Select a specific day to access all press releases published on French STEM Today.

July 2026

Mo Tu We Th Fr Sa Su
1 2 3 4 5
6 7 8 9 10 11 12
13 14 15 16 17 18 19
20 21 22 23 24 25 26
27 28 29 30 31

August 2026

Mo Tu We Th Fr Sa Su
1 2
3 4 5 6 7 8 9
10 11 12 13 14 15 16
17 18 19 20 21 22 23
24 25 26 27 28 29 30
31

September 2026

Mo Tu We Th Fr Sa Su
1 2 3 4 5 6
7 8 9 10 11 12 13
14 15 16 17 18 19 20
21 22 23 24 25 26 27
28 29 30

Press releases published on September 9, 2026

Choroideremia Research Foundation Announces New Research Grants to Advance Understanding and Treatment of CHM
6 hours ago

Choroideremia Research Foundation Announces New Research Grants to Advance Understanding and Treatment of CHM

Indeterminate EIN Presswire
Inprentus Delivers Highly Curved, Concave Diffraction Gratings for NASA Solar Science Mission
8 hours ago

Inprentus Delivers Highly Curved, Concave Diffraction Gratings for NASA Solar Science Mission

Indeterminate EIN Presswire
Quantum's Value in AI Supercomputing Will Be Decided by the Full Stack, Not Qubits Alone, Find Alice & Bob and Hyperion
10 hours ago

Quantum's Value in AI Supercomputing Will Be Decided by the Full Stack, Not Qubits Alone, Find Alice & Bob and Hyperion

Indeterminate EIN Presswire
NANOBIOTIX to Participate in the H.C. Wainwright 28th Annual Global Investment Conference
2 hours ago

NANOBIOTIX to Participate in the H.C. Wainwright 28th Annual Global Investment Conference

Indeterminate GlobeNewswire
NANOBIOTIX Participera à la Conférence H.C. Wainwright 28th Annual Global Investment
2 hours ago

NANOBIOTIX Participera à la Conférence H.C. Wainwright 28th Annual Global Investment

Indeterminate GlobeNewswire
OSE Immunotherapeutics Welcomes First Patient Dosed by Veloxis in the Phase 2 RENGEVITY-201 Trial Evaluating Pegrizeprument (VEL-101) for the Prevention of Organ Rejection in Kidney Transplant Recipients
6 hours ago

OSE Immunotherapeutics Welcomes First Patient Dosed by Veloxis in the Phase 2 RENGEVITY-201 Trial Evaluating Pegrizeprument (VEL-101) for the Prevention of Organ Rejection in Kidney Transplant Recipients

Indeterminate GlobeNewswire
OSE Immunotherapeutics se félicite de l’inclusion du premier patient traité par Veloxis dans l’étude de phase 2 RENGEVITY-201 évaluant le pegrizeprument (VEL-101) dans la prévention du rejet d’organe chez les patients transplantés rénaux
6 hours ago

OSE Immunotherapeutics se félicite de l’inclusion du premier patient traité par Veloxis dans l’étude de phase 2 RENGEVITY-201 évaluant le pegrizeprument (VEL-101) dans la prévention du rejet d’organe chez les patients transplantés rénaux

Indeterminate GlobeNewswire
GENFIT Highlights Long-Term Commercial Opportunity for its MASH Diagnostics Technology
17 hours ago

GENFIT Highlights Long-Term Commercial Opportunity for its MASH Diagnostics Technology

Indeterminate GlobeNewswire
GENFIT présente le potentiel commercial à long terme de sa technologie de diagnostic dans la MASH
17 hours ago

GENFIT présente le potentiel commercial à long terme de sa technologie de diagnostic dans la MASH

Indeterminate GlobeNewswire
VALLOUREC AND ARAMCO STRENGTHEN THEIR PARTNERSHIP THROUGH THE SIGNING OF AN AGREEMENT FOR THE SUPPLY OF OIL COUNTRY TUBULAR GOODS
17 hours ago

VALLOUREC AND ARAMCO STRENGTHEN THEIR PARTNERSHIP THROUGH THE SIGNING OF AN AGREEMENT FOR THE SUPPLY OF OIL COUNTRY TUBULAR GOODS

Indeterminate GlobeNewswire
VALLOUREC ET ARAMCO RENFORCENT LEUR PARTENARIAT AVEC LA SIGNATURE D’UN ACCORD SUR LA FOURNITURE DE TUBES OCTG
17 hours ago

VALLOUREC ET ARAMCO RENFORCENT LEUR PARTENARIAT AVEC LA SIGNATURE D’UN ACCORD SUR LA FOURNITURE DE TUBES OCTG

Indeterminate GlobeNewswire

Share this page:

Advanced Search Options

Search for:

Search scope:

Type:

Search in:

Date range:

The last

Sort by:

Sign up for:

French STEM Today

The daily local news briefing you can trust. Every day. Subscribe now.

By signing up, you agree to our Terms & Conditions.